Concord Biotech Limited (CONCORDBIO) — Capital Reinvestment Ratio
Concord Biotech Limited (CONCORDBIO) has a Capital Reinvestment Ratio of 0.45x as of March 2025, meaning it reinvests 0% of its operating cash flow (Rs2.47 Billion) in capital expenditures (Rs1.11 Billion). See CONCORDBIO equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Concord Biotech Limited Capital Reinvestment Ratio (2020–2025)
This chart tracks Concord Biotech Limited's Capital Reinvestment Ratio across 6 annual periods. Check Concord Biotech Limited (CONCORDBIO) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Concord Biotech Limited (2020–2025)
Year-by-year Capital Reinvestment Ratio for Concord Biotech Limited from 2020 to 2025. For live market cap and broader valuation context, see Concord Biotech Limited stock valuation.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.45x | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | — |